Children's Health Defense v. Food & Drug Administration

District Court, W.D. Texas·Decided January 12, 2023·No. 6:22-cv-00093·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS WACO DIVISION CHILDREN’S HEALTH DEFENSE, § DEBORAH L. ELSE, SACHA § DIETRICH, AIMEE VILLELLA § MCBRIDE, JONATHAN SHOUR, and § Case No. 6:22-CV-00093-ADA REBECCA SHOUR, § Plaintiffs, § § v. § § FOOD & DRUG ADMINISTRATION § and ROBERT M. CALIFF, § Defendants. § ORDER GRANTING DEFENDANTS’ MOTION TO DISMISS Before the Court is Defendants Food & Drug Administration (“FDA”) and FDA Commissioner Robert M. Califf’s Motion to Dismiss for Lack of Subject-Matter Jurisdiction and Failure to State a Claim filed on July 29, 2022. ECF No. 29. Plaintiffs Children’s Health Defense (“CHD”), Deborah L. Else, Sacha Dietrich, Aimee Villella McBride, Jonathan Shour, and Rebecca Shour filed a response to Defendants’ Motion on August 26, 2022. ECF No. 30. Defendants filed a reply in support of their Motion on September 16, 2022. ECF No. 31. The Court held a hearing on the Motion on November 18, 2022. ECF No. 33. After considering the parties’ briefing, the arguments at the hearing, the relevant facts, and the applicable laws, the Court GRANTS Defendants’ Motion to Dismiss for Lack of Subject- Matter Jurisdiction. The Court concludes that Plaintiffs lack standing to sue. The Court does not reach the other issues in Defendants’ Motion. I. BACKGROUND On March 27, 2020, the Secretary of the Health and Human Services determined that “circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic.” Emergency Use Authorization Declaration, 85 Fed. Reg. 18250, 18250−51 (Apr. 1, 2020). In December 2020, FDA issued emergency use

authorizations (EUAs) for the COVID-19 vaccines produced by Pfizer-BioNTech and ModernaTX, Inc. Authorizations of Emergency Use of Two Biological Products During the COVID-19 Pandemic, 86 Fed. Reg. 5200, 5201 (Jan. 19, 2021). On October 29, 2021, FDA revised the EUA to authorize administration of the Pfizer vaccine to children ages five to eleven. ECF No. 26-1 at 106 n.12. On June 17, 2022, the FDA further revised the EUA to authorize the administration of the Pfizer vaccine to children ages 6 months to 4 years. Id. at 107. The FDA states on its website that “there is an option to accept or refuse receiving the vaccine.” ECF No. 29 at 3. The FDA also states that “[s]hould you decide for your child not to receive it, it will not change your child’s standard medical care.” Id. In May 2021, CHD filed a petition with the FDA asking the agency to revoke the existing

EUAs for the COVID-19 vaccine. Id. at 3−4. The FDA denied this petition. Id. at 4. On January 24, 2022, Plaintiffs filed this action against Defendants. ECF No. 1. In its first Complaint, Plaintiffs alleged that the FDA failed to comply with the Administrative Procedures Act (APA) when it approved the COVID-19 vaccine for children. Id. ¶ 18. On April 25, 2022, Defendants filed their first Motion to Dismiss Plaintiffs’ Complaint for lack of jurisdiction and for failure to state a claim. ECF No. 18. Defendants argued that this Court lacked subject-matter jurisdiction because no Plaintiff has standing to sue and sovereign immunity bars Plaintiffs’ cause of action. Id. at 6. In the alternative, Defendants argued that the case should be dismissed for failure to plausibly state a claim for relief. Id. at 15. The Court held a hearing on Defendants’ first Motion to Dismiss on May 17, 2022. ECF No. 25. At the hearing, the Court granted Defendants’ Motion to Dismiss for lack of subject matter jurisdiction without prejudice. Id. Based on Plaintiffs’ first Complaint, the Court found that Plaintiffs lacked standing to sue and did not rule on the other grounds for Defendants’ Motion to Dismiss. The Court granted Plaintiffs leave to amend their complaint.

Plaintiffs filed their Amended Complaint on July 1, 2022. ECF No. 26. In their Amended Complaint, Plaintiffs reallege that the FDA failed to comply with the APA when it approved the COVID-19 vaccine for children. Id. ¶¶ 212−46. The individual Plaintiffs, Deborah L. Else, Sacha Dietrich, Aimee Villella McBride, Jonathan Shour, and Rebecca Shour, claim that they are in imminent risk of immediate harm because of the authorization and advertising of the COVID-19 vaccine for their children. Id. ¶¶ 9−12. Some of the individual Plaintiffs claim that they are at risk because their children may be coerced to receive the vaccine, may be forced to take the vaccine due to impending mandates, may receive the vaccine without parental consent, or may suffer adverse reactions should they be given the vaccine. Id. ¶¶ 10−11. Plaintiffs claim that “Defendants’ arbitrary and capricious actions warrant a stay, a vacatur and remand.” Id. ¶ 247. Plaintiffs also

seek a declaratory judgment that: “Defendants cannot use the emergency authorization statute to mislabel drugs as vaccines, mislabel drugs that have not been thoroughly tested as safe and effective, mislabel drugs as permitted to be compelled without informed consent, and to mislabel drugs to children that result in mandates being issued concerning those children’s access to basic services, including medical and educational services.” Id. ¶ 249. Plaintiffs further ask the Court to order the FDA to use “the regular biologic licensure process that incorporates citizen participation.” Id. Defendants filed the present Motion in response to Plaintiffs’ Amended Complaint. ECF No. 29. Defendants argue that Plaintiffs’ Amended Complaint should be dismissed because the Court lacks subject-matter jurisdiction over Plaintiffs’ claims. Id. at 5. Defendants argue that no Plaintiff has standing to sue. Id. at 6. Defendants argue that the individual Plaintiffs lack actual imminent risk of injury sufficient to meet the injury-in-fact requirement for standing. Id. at 6. Defendants argue that CHD lacks organizational and associational standing because none of its

members possess standing. Id. at 11. Defendants further argue that if the Plaintiffs have standing, sovereign immunity bars the suit. Id. at 5−6. Lastly, Defendants argue that even if this Court has subject-matter jurisdiction over the claim, Plaintiffs’ Amended Complaint should be dismissed for failure to plausibly state a claim for relief. Id. at 16. The Court held a hearing on this motion on November 18, 2022. ECF No. 33. The Court took Defendants’ Motion under advisement. Id. II. LEGAL STANDARD The law of standing is built around “the idea of separation of powers.” TransUnion LLC v. Ramirez, 141 S.Ct. 2190, 2203 (2021). For a federal court to have subject-matter jurisdiction, the plaintiff must present a case or controversy under Article III of the Constitution. Id. In other words, the plaintiff must have standing. Id. To establish standing, the plaintiff must show: (1) the plaintiff has suffered an injury in fact, (2) there is a casual connection between the injury and the

defendant’s conduct, and (3) the plaintiff’s injury would likely be redressed through judicial relief. Lujan v. Defenders of Wildlife, 504 U.S. 555, 560−61 (1992). “Under Article III, federal courts do not adjudicate hypothetical or abstract disputes.” TransUnion, 141 S.Ct. at 2203. The plaintiff must show an “injury in fact that is concrete, particularized and actual or imminent.” Id. For an injury to be “concrete,” it must be “real, and not abstract.” Id. at 2204. An injury-in-fact cannot be “‘conjectural’ or ‘hypothetical.’” Susan B. Anthony List v. Driehaus, 573 U.S. 149, 158 (2014) (quoting Lujan, 504 U.S. at 560). When evaluating whether a harm is “concrete,” courts consider “whether the asserted harm has a ‘close relationship’ to a harm traditionally recognized as providing a basis for a lawsuit in American courts—such as physical harm, monetary harm, or various intangible harms.” TransUnion, 141 S.Ct. at 2204.

Free access — add to your briefcase to read the full text and ask questions with AI

Children's Health Defense v. Food & Drug Administration, (W.D. Tex. 2023).

Children's Health Defense v. Food & Drug Administration (Children's Health Defense v. Food & Drug Administration) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Sierra Club v. Glickman
156 F.3d 606 (Fifth Circuit, 1998)
Havens Realty Corp. v. Coleman
455 U.S. 363 (Supreme Court, 1982)
Lujan v. Defenders of Wildlife
504 U.S. 555 (Supreme Court, 1992)
Hein v. Freedom From Religion Foundation, Inc.
551 U.S. 587 (Supreme Court, 2007)
New York Public Interest Research Group v. Whitman
321 F.3d 316 (Second Circuit, 2003)
Clapper v. Amnesty International USA
133 S. Ct. 1138 (Supreme Court, 2013)
Tummino v. Torti
603 F. Supp. 2d 519 (E.D. New York, 2009)
Spokeo, Inc. v. Robins
578 U.S. 330 (Supreme Court, 2016)
Center for Bio Diversity v. EPA
937 F.3d 533 (Fifth Circuit, 2019)
Jarrod Stringer v. David Whitley
942 F.3d 715 (Fifth Circuit, 2019)
TransUnion LLC v. Ramirez
594 U.S. 413 (Supreme Court, 2021)
Glennborough Homeowners Ass'n v. USPS
21 F.4th 410 (Sixth Circuit, 2021)
Baur v. Veneman
352 F.3d 625 (Second Circuit, 2003)